Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial

Background Adjuvant abemaciclib plus endocrine therapy previously showed a significant improvement in invasive disease-free survival and distant relapse-free survival in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2; also known as ERBB2)-negative, node-positive, high-risk, early breast cancer. Here, we report updated results from an interim analysis to assess overall survival as well as invasive disease-free survival and distant relapse-free survival with additional follow-up. Methods In monarchE, an open-label, randomised, phase 3 trial, adult patients (aged >= 18 years) who had hormone receptor-positive, HER2-negative, node-positive, early breast cancer at a high risk of recurrence with an Eastern Cooperative Oncology Group performance status of 0 or 1 were recruited from 603 sites including hospitals and academic and community centres in 38 countries. Patients were randomly assigned (1:1) by means of an interactive web-based response system (block size of 4), stratified by previous chemotherapy, menopausal status, and region, to receive standard-of-care endocrine therapy of physician's choice for up to 10 years with or without abemaciclib 150 mg orally twice a day for 2 years (treatment period). All therapies were administered in an open-label manner without masking. High-risk disease was defined as either four or more positive axillary lymph nodes, or between one and three positive axillary lymph nodes and either grade 3 disease or tumour size of 5 cm or larger (cohort 1). A smaller group of patients were enrolled with between one and three positive axillary lymph nodes and Ki-67 of at least 20% as an additional risk feature (cohort 2). This was a prespecified overall survival interim analysis planned to occur 2 years after the primary outcome analysis for invasive disease-free survival. Efficacy was assessed in the intention-to-treat population. Safety was assessed in all treated patients. The study is registered with ClinicalTrials.gov, NCT03155997, and is ongoing. Findings Between July 17, 2017, and Aug 12, 2019, 5637 patients were randomly assigned (5601 [99.4%] were women and 36 [0middot6%] were men). 2808 were assigned to receive abemaciclib plus endocrine therapy and 2829 were assigned to receive endocrine therapy alone. At a median follow-up of 42 months (IQR 37-47), median invasive disease-free survival was not reached in either group and the invasive disease-free survival benefit previously reported was sustained: HR 0middot664 (95% CI 0middot578-0middot762, nominal p<0.0001). At 4 years, the absolute difference in invasive disease-free survival between the groups was 6middot4% (85middot8% [95% CI 84middot2-87middot3] in the abemaciclib plus endocrine therapy group vs 79middot4% [77middot5-81middot1] in the endocrine therapy alone group). 157 (5middot6%) of 2808 patients in the abemaciclib plus endocrine therapy group died compared with 173 (6middot1%) of 2829 patients in the endocrine therapy alone group (HR 0middot929, 95% CI 0middot748-1middot153; p=0middot50). The most common grade 3-4 adverse events were neutropenia (in 548 [19middot6%] of 2791 patients receiving abemaciclib plus endocrine therapy vs 24 [0middot9%] of 2800 patients in the endocrine therapy alone group), leukopenia (318 [11middot4%] vs 11 [0middot4%]), and diarrhoea (218 [7middot8%] vs six [0middot2%]). Serious adverse events occurred in 433 (15middot5%) of 2791 patients receiving abemaciclib plus endocrine therapy versus 256 (9middot1%) of 2800 receiving endocrine therapy. There were two treatment-related deaths in the abemaciclib plus endocrine therapy group (diarrhoea and pneumonitis) and none in the endocrine therapy alone group. Interpretation Adjuvant abemaciclib reduces the risk of recurrence. The benefit is sustained beyond the completion of treatment with an absolute increase at 4 years, further supporting the use of abemaciclib in patients with high-risk hormone receptor-positive, HER2-negative early breast cancer. Further follow-up is needed to establish whether overall survival can be improved with abemaciclib plus endocrine therapy in these patients. Funding Eli Lilly. Copyright (c) 2022 Published by Elsevier Ltd. All rights reserved.